Pigment epithelium-derived factor (PEDF) negates hyperandrogenic PCOS features

Area of Science:

• Reproductive Endocrinology
• Molecular Biology
• Cell Biology

Background:

• Polycystic ovary syndrome (PCOS) is a common endocrine disorder causing infertility, characterized by hyperandrogenism.
• Hyperandrogenism in PCOS is linked to increased ovarian vascular endothelial growth factor (VEGF) and cytokines.
• Pigment epithelium-derived factor (PEDF) exhibits anti-angiogenic and anti-inflammatory properties, potentially counteracting PCOS-related ovarian dysfunction.

Purpose of the Study:

• To investigate the role of PEDF in PCOS and ovarian hyperstimulation syndrome (OHSS).
• To evaluate the therapeutic potential of recombinant PEDF (rPEDF) in PCOS and OHSS models.

Main Methods:

• Established in vivo (DHT-exposed mice) and in vitro (human granulosa cells) PCOS models.
• Administered rPEDF to PCOS and OHSS models.
• Assessed mRNA levels of IL-6, VEGF, Amh, IL-8, and PEDF.
• Investigated the anti-inflammatory mechanism of PEDF via the PPARγ pathway.

Main Results:

• rPEDF treatment reduced IL-6, VEGF, and Amh mRNA levels in PCOS mice.
• rPEDF alleviated all symptoms in OHSS-induced PCOS mice.
• DHT downregulated PEDF and upregulated IL-6/IL-8 in human granulosa cells; rPEDF co-treatment attenuated this effect.
• PEDF's anti-inflammatory action is mediated through the PPARγ pathway.

Conclusions:

• rPEDF treatment can normalize the hyperandrogenism-induced angiogenic-inflammatory imbalance in PCOS ovaries.
• PEDF demonstrates therapeutic potential for treating PCOS complications, including OHSS.